• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

取代基对金属环配合铱(III)配合物与 DNA 和蛋白质结合及抗癌活性的影响。

Influence of substituents on DNA and protein binding of cyclometalated Ir(iii) complexes and anticancer activity.

机构信息

Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi 221 005, U.P., India.

出版信息

Dalton Trans. 2017 Jul 4;46(26):8572-8585. doi: 10.1039/c7dt01015j.

DOI:10.1039/c7dt01015j
PMID:28640302
Abstract

Synthesis of terpyridyl based ligands 3-([2,2':6',2''-terpyridin]-4'-yl)-7-methoxy-2-(methylthio)-quinolone, (L1); 3-([2,2':6',2''-terpyridin]-4'-yl)-6-methoxyquinolin-2(1H)-one, (L2); 3-([2,2'-:6',2''-terpyridin]-4'-yl)-6-methylquinolin-2(1H)-one (L3) and cyclometalated iridium(iii) complexes [[Ir(ppy)L1]PF (1), [Ir(ppy)L2]PF (2), [Ir(ppy)L3]PF (3) (2-phenylpyridine = Hppy)] involving these ligands has been described. The ligands L1-L3 and complexes 1-3 have been thoroughly characterized by elemental analyses, spectral studies (IR, H, C NMR, UV/vis and fluorescence) ESI-MS, and the structure of 3 has been unambiguously authenticated by single crystal X-ray analyses. UV/vis, fluorescence and circular dichroism spectroscopic studies showed rather efficient binding of 1 with CT-DNA (calf thymus DNA) and BSA (bovine serum albumin) relative to 2 and 3. Molecular docking studies unveiled binding of 1-3 with minor groove of CT-DNA via van der Waal's forces and electrostatically with the hydrophobic moiety of HSA (human serum albumin). The ligands and complexes exhibited moderate cytotoxicity towards MDA-MB-231 (breast cancer cell line) and significant influence on HeLa (cervical cancer cell line) cells. Cytotoxicity, morphological changes, and apoptosis have been followed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay, Hoechst 33342/PI (PI = propidium iodide) staining, cell cycle analysis by FACS (fluorescence activated cell sorting), and ROS (reactive oxygen species) generation by DCFH-DA (dichlorodihydrofluorescein diacetate) dye. Confocal microscopy images revealed that the drug efficiently initiates apoptosis in the cell cytosol. The IC values showed superior cytotoxicity of 1-3 against the HeLa cell line relative to cisplatin, and their ability to induce apoptosis is in the order 1 > 2 > 3.

摘要

已合成了三种基于三联吡啶的配体

3-([2,2':6',2''-三联吡啶]-4'-基)-7-甲氧基-2-(甲硫基)-喹啉酮(L1);3-([2,2':6',2''-三联吡啶]-4'-基)-6-甲氧基喹啉-2(1H)-酮(L2);3-([2,2':6',2''-三联吡啶]-4'-基)-6-甲基喹啉-2(1H)-酮(L3),以及相应的环金属铱(III)配合物[Ir(ppy)L1]PF(1)、[Ir(ppy)L2]PF(2)、[Ir(ppy)L3]PF(3)(2-苯基吡啶=Hppy)。这些配体和配合物已通过元素分析、光谱研究(IR、H、C NMR、UV/vis 和荧光)、ESI-MS 等方法进行了全面表征,并通过单晶 X 射线分析明确鉴定了 3 的结构。紫外-可见吸收光谱、荧光光谱和圆二色光谱研究表明,与 2 和 3 相比,1 与 CT-DNA(小牛胸腺 DNA)和 BSA(牛血清白蛋白)的结合更为有效。分子对接研究表明,1-3 通过范德华力和与 HSA(人血清白蛋白)疏水区的静电相互作用与 CT-DNA 的小沟结合。这些配体和配合物对 MDA-MB-231(乳腺癌细胞系)具有中等的细胞毒性,对 HeLa(宫颈癌细胞系)细胞具有显著的影响。通过 MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐)测定、Hoechst 33342/PI(PI=碘化丙啶)染色、荧光激活细胞分选(FACS)的细胞周期分析以及 DCFH-DA(二氯二氢荧光素二乙酸酯)染料的 ROS(活性氧)生成,研究了细胞毒性、形态变化和细胞凋亡。共聚焦显微镜图像显示,该药物可有效在细胞质中诱导细胞凋亡。IC 值表明,与顺铂相比,1-3 对 HeLa 细胞系的细胞毒性更强,其诱导凋亡的能力顺序为 1>2>3。

相似文献

1
Influence of substituents on DNA and protein binding of cyclometalated Ir(iii) complexes and anticancer activity.取代基对金属环配合铱(III)配合物与 DNA 和蛋白质结合及抗癌活性的影响。
Dalton Trans. 2017 Jul 4;46(26):8572-8585. doi: 10.1039/c7dt01015j.
2
Anticancer Activity of Iridium(III) Complexes Based on a Pyrazole-Appended Quinoline-Based BODIPY.基于吡唑连接的喹啉基BODIPY的铱(III)配合物的抗癌活性
Inorg Chem. 2017 Oct 16;56(20):12232-12247. doi: 10.1021/acs.inorgchem.7b01693. Epub 2017 Sep 28.
3
Mixed-ligand iridium(iii) complexes as photodynamic anticancer agents.混合配体铱(III)配合物作为光动力抗癌剂。
Dalton Trans. 2017 Aug 29;46(34):11395-11407. doi: 10.1039/c7dt02273e.
4
Cu(II), Ni(II) complexes derived from chiral Schiff-base ligands: Synthesis, characterization, cytotoxicity, protein and DNA-binding properties.源自手性席夫碱配体的铜(II)、镍(II)配合物:合成、表征、细胞毒性、蛋白质和DNA结合特性
J Photochem Photobiol B. 2016 Oct;163:403-12. doi: 10.1016/j.jphotobiol.2016.09.005. Epub 2016 Sep 5.
5
Interaction of ferrocene appended Ru(II), Rh(III) and Ir(III) dipyrrinato complexes with DNA/protein, molecular docking and antitumor activity.二茂铁取代的钌(II)、铑(III)和铱(III)二吡咯甲川配合物与 DNA/蛋白质的相互作用、分子对接和抗肿瘤活性。
Eur J Med Chem. 2014 Sep 12;84:17-29. doi: 10.1016/j.ejmech.2014.06.052. Epub 2014 Jun 26.
6
Pyrazole appended quinoline-BODIPY based arene ruthenium complexes: their anticancer activity and potential applications in cellular imaging.吡唑并[1,5-a]喹啉-BODIPY 衍生芳烃钌配合物:它们的抗癌活性及在细胞成像中的潜在应用。
Dalton Trans. 2018 Dec 11;47(48):17500-17514. doi: 10.1039/c8dt02947d.
7
Synthesis and preliminary biological evaluation for the anticancer activity of organochalcogen (S/se) tethered chrysin-based organometallic Ru(η-p-cymene) complexes.有机硫(S/Se)键连白杨素基有机金属钌(η-p-cymene)配合物的合成及抗癌活性的初步评价。
J Biomol Struct Dyn. 2019 Aug;37(13):3337-3353. doi: 10.1080/07391102.2018.1513867. Epub 2018 Nov 19.
8
Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.新型多功能亚胺-N-杂环卡宾半夹心型铱(III)配合物作为溶酶体靶向抗癌剂。
Inorg Chem. 2018 Sep 4;57(17):11087-11098. doi: 10.1021/acs.inorgchem.8b01656. Epub 2018 Aug 22.
9
Anticancer and antibacterial activity in vitro evaluation of iridium(III) polypyridyl complexes.三价铱配合物的体外抗肿瘤和抗菌活性评价。
J Biol Inorg Chem. 2019 Mar;24(2):151-169. doi: 10.1007/s00775-018-1635-8. Epub 2018 Dec 18.
10
Induction of apoptosis in SGC-7901 cells by iridium(III) complexes via endoplasmic reticulum stress-mitochondrial dysfunction pathway.通过内质网应激-线粒体功能障碍途径诱导 SGC-7901 细胞凋亡的铱(III)配合物。
J Biol Inorg Chem. 2022 Aug;27(4-5):455-469. doi: 10.1007/s00775-022-01943-6. Epub 2022 Jul 11.

引用本文的文献

1
Cyclometalated complexes: promising metallodrugs in the battle against cancer.环金属化配合物:抗癌斗争中颇具潜力的金属药物。
RSC Med Chem. 2025 Jul 31. doi: 10.1039/d5md00178a.
2
Research Progress of Metal Anticancer Drugs.金属抗癌药物的研究进展
Pharmaceutics. 2023 Dec 11;15(12):2750. doi: 10.3390/pharmaceutics15122750.
3
Selective anticancer activities of ruthenium(II)-tetrazole complexes and their mechanistic insights.钌(II)-四唑配合物的选择性抗癌活性及其作用机制研究。
Biometals. 2021 Aug;34(4):795-812. doi: 10.1007/s10534-021-00308-x. Epub 2021 Apr 26.